clinical trial · NCT05789056
Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome
Netherton SyndromeQRX003, 4% Lotion
brief summary
To assess the safety, tolerability, and efficacy of QRX003 lotion (4%) when added to standard of care treatment regimen, including systemic therapy in subjects with Netherton syndrome
started
Mar 14, 2023
primary completion
Dec 30, 2025
completion
Dec 30, 2025
last updated
Apr 2, 2025
official title
A Multicenter, Open Label Study of QRX003 Lotion in Subjects With Netherton Syndrome
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol